-
Mashup Score: 2Common Misconceptions About Waldenström Macroglobulinemia | Dana-Farber Cancer Institute - 5 month(s) ago
Published: November 16, 2023Written by: Rob LevyMedically Reviewed By: Jorge Castillo, MDWaldenström macroglobulinemia, a rare form of non-Hodgkin lymphoma, has its share of eccentricities. One of the hallmarks of the disease, for example, is an overabundance of a particular protein, yet other conditions may also have that feature. It’s also not unusual for patients to … Read more
Source: blog.dana-farber.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study - 8 month(s) ago
The phase III ASPEN study demonstrated the comparable efficacy and improved safety of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia (WM). Here, we report long-term follow-up outcomes from ASPEN. The primary end point was the sum of very good partial response (VGPR) + complete response (CR) rates; secondary and exploratory end points were also reported. Cohort 1 comprised 201 patients (myeloid differentiation primary response 88–mutant WM: 102 receiving zanubrutinib; 99 receiving ibrutinib); cohort 2 comprised 28 patients (myeloid differentiation primary response 88 wild-type WM: 28 zanubrutinib; 26 efficacy evaluable). At 44.4-month median follow-up, VGPR + CR rates were 36.3% with zanubrutinib versus 25.3% with ibrutinib in cohort 1 and 30.8% with one CR in cohort 2. In patients with CXC motif chemokine receptor 4 mutation, VGPR + CR rates were 21.2% with zanubrutinib versus 10.0% with ibrutinib (cohort 1). Median progression-free survival and overall su
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Pirtobrutinib Displays High Response Rate in Pretreated Waldenström Macroglobulinemia - 1 year(s) ago
Heavily pretreated patients with Waldenström macroglobulinemia demonstrated encouraging responses with pirtobrutinib, a non-covalent BTK inhibitor.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Exciting Advances in Waldenström Macroglobulinemia (WM) Treatment - Patient Empowerment Network - 2 year(s) ago
Dr. Shayna Sarosiek from reviews promising developments in WM treatment, including immunotherapy and BTK inhibitors.
Source: Patient Empowerment NetworkCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
With the introduction of multiple new effective therapeutic options for the treatment of macroglobulinemia, a structured approach to management of this rare lymphoma is currently needed. A review of phase II and III treatment trials over the past 20 years was performed, and high-quality trials are summarized in this manuscript. Because of the lack of large prospective trials comparing different…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3
With the introduction of multiple new effective therapeutic options for the treatment of macroglobulinemia, a structured approach to management of this rare lymphoma is currently needed. A review of phase II and III treatment trials over the past 20 years was performed, and high-quality trials are summarized in this manuscript. Because of the lack of large prospective trials comparing different…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Eponyms in Oncology: Waldenström Macroglobulinemia - 2 year(s) ago
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of Waldenström macroglobulinemia.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Venetoclax is safe and highly active in patients with previously treated WM, including those who previously received BTKis. CXCR4 mutation status did not affect treatment response.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2When to Treat as Important as Which Drug to Use in WM - 3 year(s) ago
When to initiate treatment for patients newly diagnosed with Waldenstrom macroglobulinemia (WM) is as important as which drug to use, says expert.
Source: MedscapeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Current research in Waldenström’s macroglobulinemia - 4 year(s) ago
Véronique Leblond, MD, Hematology at Pitié Salpêtrière Hospital, Paris, France, outlines current research approaches in the treatment of Waldenström’s macroglobulinemia…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
#WaldenströmMacroglobulinemia has its share of eccentricities. We asked Jorge Castillo, MD to discuss some common misconceptions about Waldenström and how they can be dispelled. https://t.co/Gtt5v7KqPC https://t.co/Ew3HLiXb3O